BACKGROUND: Subgroups of patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) exhibit suboptimal outcomes after standard therapies, including oral kinase inhibitors. We and others have previously reported on safety and efficacy of autologous CD19-targeted CAR T-cells for these patients; here we report safety and long-term follow-up of CAR T-cell therapy with or without conditioning chemotherapy for patients with R/R CLL and indolent B-cell non-Hodgkin lymphoma (B-NHL). METHODS: We conducted a phase 1 clinical trial investigating CD19-targeted CAR T-cells incorporating a CD28 costimulatory domain (19-28z). Seventeen of 20 patients received conditioning chemotherapy prior to CAR T-cell infusion. Five patients with CLL received ibrutinib at the time of autologous T-cell collection and/or CAR T-cell administration. RESULTS: This analysis included 16 patients with R/R CLL and 4 patients with R/R indolent B-NHL. Cytokine release syndrome (CRS) was observed in all 20 patients but grades 3 and 4 CRS and neurological events were uncommon (10% for each). Ex vivo expansion of T-cells and proportions of CD4+/CD8+ CAR T-cells with CD62L+CD127+ immunophenotype were significantly greater in patients on ibrutinib at leukapheresis. Three of 12 evaluable CLL patients receiving conditioning chemotherapy achieved CR (two had minimal residual disease-negative CR). All patients achieving CR remained progression-free at median follow-up of 53 months. CONCLUSION: Conditioning chemotherapy and 19-28z CAR T-cells were acceptably tolerated across investigated dose levels in heavily pretreated patients with R/R CLL and indolent B-NHL, and a subgroup of patients achieved durable CR. Ibrutinib therapy may modulate autologous T-cell phenotype. TRIAL REGISTRATION: ClinicalTrials.gov NCT00466531. FUNDING: Juno Therapeutics.
BACKGROUND: Subgroups of patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) exhibit suboptimal outcomes after standard therapies, including oral kinase inhibitors. We and others have previously reported on safety and efficacy of autologous CD19-targeted CAR T-cells for these patients; here we report safety and long-term follow-up of CAR T-cell therapy with or without conditioning chemotherapy for patients with R/R CLL and indolent B-cell non-Hodgkin lymphoma (B-NHL). METHODS: We conducted a phase 1 clinical trial investigating CD19-targeted CAR T-cells incorporating a CD28 costimulatory domain (19-28z). Seventeen of 20 patients received conditioning chemotherapy prior to CAR T-cell infusion. Five patients with CLL received ibrutinib at the time of autologous T-cell collection and/or CAR T-cell administration. RESULTS: This analysis included 16 patients with R/R CLL and 4 patients with R/R indolent B-NHL. Cytokine release syndrome (CRS) was observed in all 20 patients but grades 3 and 4 CRS and neurological events were uncommon (10% for each). Ex vivo expansion of T-cells and proportions of CD4+/CD8+ CAR T-cells with CD62L+CD127+ immunophenotype were significantly greater in patients on ibrutinib at leukapheresis. Three of 12 evaluable CLL patients receiving conditioning chemotherapy achieved CR (two had minimal residual disease-negative CR). All patients achieving CR remained progression-free at median follow-up of 53 months. CONCLUSION: Conditioning chemotherapy and 19-28z CAR T-cells were acceptably tolerated across investigated dose levels in heavily pretreated patients with R/R CLL and indolent B-NHL, and a subgroup of patients achieved durable CR. Ibrutinib therapy may modulate autologous T-cell phenotype. TRIAL REGISTRATION: ClinicalTrials.gov NCT00466531. FUNDING: Juno Therapeutics.
Entities:
Keywords:
Cancer immunotherapy; Clinical Trials; Immunology; Leukemias
Authors: Güllü Görgün; Tobias A W Holderried; David Zahrieh; Donna Neuberg; John G Gribben Journal: J Clin Invest Date: 2005-06-16 Impact factor: 14.808
Authors: Katherine I Lin; Constantine S Tam; Michael J Keating; William G Wierda; Susan O'Brien; Susan Lerner; Kevin R Coombes; Ellen Schlette; Alessandra Ferrajoli; Lynn L Barron; Thomas J Kipps; Laura Rassenti; Stefan Faderl; Hagop Kantarjian; Lynne V Abruzzo Journal: Blood Date: 2008-12-02 Impact factor: 22.113
Authors: Michael Hallek; Bruce D Cheson; Daniel Catovsky; Federico Caligaris-Cappio; Guillaume Dighiero; Hartmut Döhner; Peter Hillmen; Michael J Keating; Emili Montserrat; Kanti R Rai; Thomas J Kipps Journal: Blood Date: 2008-01-23 Impact factor: 22.113
Authors: Lindsey E Roeker; Peter Dreger; Jennifer R Brown; Oscar B Lahoud; Toby A Eyre; Danielle M Brander; Alan Skarbnik; Catherine C Coombs; Haesook T Kim; Matthew Davids; Steven T Manchini; Gemlyn George; Nirav Shah; Timothy J Voorhees; Kim H Orchard; Harriet S Walter; Arvind K Arumainathan; Andrea Sitlinger; Jae H Park; Mark B Geyer; Andrew D Zelenetz; Craig S Sauter; Sergio A Giralt; Miguel-Angel Perales; Anthony R Mato Journal: Blood Adv Date: 2020-08-25
Authors: Ana Carolina Caballero; Laura Escribà-Garcia; Carmen Alvarez-Fernández; Javier Briones Journal: Front Immunol Date: 2022-07-06 Impact factor: 8.786
Authors: Jordan Gauthier; Evandro D Bezerra; Alexandre V Hirayama; Salvatore Fiorenza; Alyssa Sheih; Cassie K Chou; Erik L Kimble; Barbara S Pender; Reed M Hawkins; Aesha Vakil; Tinh-Doan Phi; Rachel N Steinmetz; Abby W Jamieson; Merav Bar; Ryan D Cassaday; Aude G Chapuis; Andrew J Cowan; Damian J Green; Hans-Peter Kiem; Filippo Milano; Mazyar Shadman; Brian G Till; Stanley R Riddell; David G Maloney; Cameron J Turtle Journal: Blood Date: 2021-01-21 Impact factor: 25.476